Avsar.

Consumer Discretionary · Pharmacy Retail

Entero Healthcare Solutions Ltd (ENTERO)

₹1,575.20

Mkt cap
₹6,863 Cr
P/E ratio
53.20
P/B
4.06
Div yield
0.00%
ROE
6.94%
ROCE
10.50%
EPS (TTM)
₹29.61
Book value
₹388
52W range
944–1,920
Sector
Consumer Discretionary

Price history

Previous close

Incorporated in 2018, Entero Healthcare Solutions Ltd is in the business of distribution and marketing of pharmaceutical and surgical products and allied services [1]

NSE ENTEROBSE 544122
Health check
Mixed
ValuationFair
ProfitabilityWeak
GrowthHigh
TechnicalsNeutral
52-week range
−17.96% from high
₹1,575
₹944+66.86% from low₹1,920
Current
₹1,575.20
Prev close
₹1,559.30
Day
+1.02%
Price performance
1D
+0.37%
1W
+6.58%
1M
−11.33%
3M
+25.91%
6M
+31.36%
1Y
+41.21%
YTD
+40.20%

Financials

Revenue, profit & margin
P/E ratio
53.2×
ENTERO is 23% above the sector median of 43.1×
ENTERO53.2×
Sector median43.1×
 Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Trend
Sales8999969931,0341,0971,3011,3591,3391,4041,5711,7071,9101,940
Expenses8739689641,0051,0671,2581,3091,2901,3541,5091,6391,8241,844
Operating Profit26292929304250495062688697
OPM %2.9%2.9%2.9%2.8%2.8%3.3%3.7%3.6%3.6%4.0%4.0%4.5%5%
Other Income122913118765-443
Interest14181617101110101112141721
Depreciation66677788910101512
Profit before tax77814273539373645405867
Tax %6%23%16%-56%25%25%25%16%17%18%16%22%22%
Net Profit65721212629313037344552
EPS in Rs15.183.194.224.824.625.435.855.906.397.266.356.448.77
Raw PDF

Earnings

Results dates & reactions
Next results
4 Nov '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +3.63% · closed higher next day 2 of last 2
 Q4FY25†Q1FY27
Broadcast5 Oct '26◦7 Aug '26◦
Earnings day+1.44%+5.83%
+1 day+0.95%+14.85%
+5 days−4.88%+12.79%
+15 days−5.78%+45.64%
+30 days—+48.21%
FilingXBRLXBRL

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Results analysis

Shareholding

as of Sep 2026
52.40%Promoter
Promoters52.40%
FIIs5.76%1.40
DIIs21.16%5.68
Public20.67%7.10
Ownership trend

Peers

2 companies
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Medplus Health₹579.9033.026,9680.00%56+1.05%2,037+21.30%12.56%
Entero Healthcar₹1,575.2053.186,8630.00%52+37.27%1,941+38.23%10.47%
Median: 2 Co.₹1,077.5543.106,9150.00%54+19.16%1,989+29.77%11.52%

Filings

Annual reports3
Annual Report 2026Annual Report 2025Annual Report 2024
Concall transcripts29
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025TranscriptFeb 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptJun 2024
Credit ratings3
Rating update 3 Dec 2025fitchRating update 9 Sep 2024fitchRating update 11 Feb 2021fitch
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 Oct - Intimation of Earnings call on Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026Board Meeting Intimation for Consider, Approve And Take On Record The Unaudited Standalone And Consolidated Financial Results (Along With Limited Review Report) For The Quarter Ended September 30, 2026 22 Oct - Board meets on November 4, 2026 to approve Q2 FY2026-27 standalone and consolidated results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 13 Oct - Regulation 74(5) certificate filed for quarter ended September 30, 2026; no demat or remat requests received.Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 12 Oct - Intimation of allotment of Equity Shares upon exercise of stock options under the Entero Employee Stock Option Plan 2023Closure of Trading Window 23 Sep - Trading window closed from October 1, 2026 until 48 hours after Q2 FY2026-27 results.